Dharmaj Crop Guard Ltd
DHARMAJDharmaj Crop Guard Ltd is coiled. The quarters are improving, yet the P/E sits at the 30th percentile of its own 1-year range — the business is moving before the market.
The sharpest disagreement: profits are rising, but only 55% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (9 weeks in) while the P/E sits at the 30th percentile of its own 1-year range. Underneath, the last four quarters read improving, and 55% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Dharmaj Crop Guard Ltd trades at ₹268, in a confirmed uptrend and 9 weeks into that stage. That is +1.8% against its own 200-day average. It sits at 28% of a 52-week range of ₹228 to ₹372. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (5 weeks and counting).
Today the stock is in a confirmed uptrend — week 9 of stage 2, confirmed. At ₹268 it trades +1.8% versus its 200-day average and sits at 28% of its 52-week range (₹228–₹372).
Against the market, two honest reads. Cumulative: over the last 3.6 years the stock moved +7% while the NIFTY 500 moved +47% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (5 weeks and counting; last ahead the week of 2026-07-01) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Dharmaj Crop Guard Ltd trades at 16.6× P/E, near the bottom of its own range — cheaper only 30% of the time. Its long-run median P/E is 17.2×, measured across 1.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 16.6× is near the bottom of its own range — cheaper only 30% of the time, against a long-run median of 17.2× measured over 1.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +56.8% against a −18.2% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Dharmaj Crop Guard Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 0 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +19.7% | — | — | — |
| Profit | +57.1% | — | — | — |
| EPS | +56.8% | — | — | — |
| Share price | −18.2% | +16.5% | — | — |
4-Factor Sector Score
61.1/100 — rank 5 of 24 in Pesticides/Agrochemicals · 62% evidence confidence
Dharmaj Crop Guard Ltd scores 61.1 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 5. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 23.8 + 12.9 + 10.6 + 13.8 = 61.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Dharmaj Crop Guard Ltd reported ₹234 Cr of revenue in the Mar 26 quarter, +11.4% year on year. That is the 4th straight quarter of year-on-year growth. Over 2 years it has compounded at 31.9% a year. The last full year, FY26, came in at ₹1,138 Cr. The last four reported quarters add to ₹1,138 Cr.
FY26 revenue came in at ₹1,138 Cr (+19.7% on the year), capping 2 years at 31.9% compound. The latest quarter (Mar 26) printed ₹234 Cr, +11.4% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +18.9% growth against the decade's 31.9% — the current year is running slower than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Dharmaj Crop Guard Ltd's operating margin is 4.5% in the Mar 26 quarter, +2.7 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 8.0% to 10.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 4.5%, +2.7 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 8.0%–10.0%.
Why the margin moved: operating margin went +2.7 pp year on year while gross margin went +4.7 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Dharmaj Crop Guard Ltd earned ₹4.0 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹55.0 Cr. The 2-year compound rate is 11.8%. That is 1.7% of the quarter's revenue. The same quarter a year earlier lost ₹2.5 Cr. 1 of the last 8 reported quarters were loss-making.
Mar 26 profit was ₹4.0 Cr, null year on year. On the full year, FY26 printed ₹55.0 Cr (+57.1%), and the 2-year compound rate is 11.8%.
Pace comparison, last four quarters: profit +21.0% vs revenue +18.9%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 55% of Dharmaj Crop Guard Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹28.0 Cr of operating cash against ₹55.0 Cr of profit. After ₹27.0 Cr of capital spending, ₹1.0 Cr was left as free cash.
FY26: operating cash of ₹28.0 Cr against reported profit of ₹55.0 Cr, leaving free cash of ₹1.0 Cr after ₹27.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 55% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 55%: the cash cycle held roughly steady between FY24 and FY26 — so conversion tracks profitability rather than the cycle. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Dharmaj Crop Guard Ltd's cash conversion cycle runs 87 days in FY26, up from 84 days in FY24. Capital spending ran ₹49.0 Cr over the last 2 years. At FY26 sales of ₹1,138 Cr each day of that cycle holds about ₹3.1 Cr, so roughly ₹271 Cr sits inside the business at any moment.
FY26: debtors at 90 days, inventory at 86 days — roughly 2.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 87 days, looser than FY24's 84.
The full loop: cash goes out to suppliers and production on day 0; stock waits 86 days to sell; customers pay about 90 days after that; and suppliers themselves are paid at 89 days — netting out to the 87-day cycle.
In money terms: at FY26 sales of ₹1,138 Cr, each day of the cycle holds about ₹3.1 Cr — so the 87-day loop keeps roughly ₹271 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹49.0 Cr over the last 2 fiscal years against ₹37.0 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹6.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Dharmaj Crop Guard Ltd earns a ROCE of 16% in FY26. Return on invested capital clears the cost of that capital by −1.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 4.8% net margin on 1.35× asset turns.
FY26 ROCE is 16%.
🚨 Why the return is what it is — the wiring (FY26): 4.8% net margin × 1.35× asset turns × 1.87× balance-sheet leverage ≈ 12.1% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 10.7% − 12.0% = a −1.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Dharmaj Crop Guard Ltd carries total debt of ₹132 Cr against shareholder equity of ₹449 Cr as of Mar 26, a debt-to-equity of 0.29 — effectively unlevered. On the annual view that ratio went from 0.44 in FY22 to 0.29 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹132 Cr against shareholder equity of ₹449 Cr — a debt-to-equity of 0.29. On the annual view, debt-to-equity went from 0.44 (FY22) to 0.29 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 3.8 points of Dharmaj Crop Guard Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 3.1% of the company. Domestic institutions moved +0.4 points over the same window, to 0.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −3.8 points over 8 quarters to 3.1%; Domestic institutions: +0.4 points over 8 quarters to 0.5%; Promoters: +0.0 points over 8 quarters to 70.4%.
🚨 Why the register moved: foreign institutions drove it (−3.8 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Dharmaj Crop Guard Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Titan Biotech Ltd524717 | 69.3/100Favorable setup78% evidence | ASLEEP | 29.1/35 Revenue 31.8% · PAT 38.7% · OPM change 6.9 pp 83% evidence | 20.2/25 ROCE 22.8% · OPM 19.9% 76% evidence | 6.0/20 P/E 57.8× · PEG — 50% evidence | 14.0/20 RS sector 41.7% · RS bench 39.3% · 1Y 371.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 20.2 + 6 + 14 = 69.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Sharda Cropchem LtdSHARDACROP | 65.3/100Favorable setup97% evidence | ASLEEP | 23.7/35 Revenue 18.5% · PAT 49% · OPM change -5 pp 95% evidence | 18.5/25 ROCE 30.2% · OPM 17% 95% evidence | 19.2/20 P/E 11.8× · PEG 0.26 100% evidence | 3.9/20 RS sector -10.9% · RS bench -13.7% · 1Y -24.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 23.7 + 18.5 + 19.2 + 3.9 = 65.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.9% and the one-year return is -24.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Punjab Chemicals & Crop Protection LtdPUNJABCHEM | 61.8/100Mixed-positive evidence81% evidence | ASLEEP | 22.7/35 Revenue 8.2% · PAT 43.5% · OPM change 1 pp 95% evidence | 18.3/25 ROCE 18.6% · OPM 12% 95% evidence | 12.1/20 P/E 21× · PEG — 50% evidence | 8.7/20 RS sector -6.2% · RS bench -2.6% · 1Y -13.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 22.7 + 18.3 + 12.1 + 8.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Bayer CropScience LtdBAYERCROP | 61.7/100Mixed-positive evidence70% evidence | ASLEEP | 21.4/35 Revenue 3.7% · PAT 21.7% · OPM change 2.1 pp 83% evidence | 19.1/25 ROCE 20.1% · OPM 18.4% 95% evidence | 8.5/20 P/E 387× · PEG — 15% evidence | 12.7/20 RS sector 9.4% · RS bench -10.7% · 1Y -33.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.4 + 19.1 + 8.5 + 12.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Dharmaj Crop Guard Ltdthis pageDHARMAJ | 61.1/100Mixed-positive evidence62% evidence | TURNING | 23.8/35 Revenue 19.6% · PAT 56.9% · OPM change 2.7 pp 62% evidence | 12.9/25 ROCE 16.4% · OPM 4.5% 95% evidence | 10.6/20 P/E 16.6× · PEG — 15% evidence | 13.8/20 RS sector 5% · RS bench -2.5% · 1Y -13.2%4 of 10 weeks ahead 70% evidence |
| Exact sum: 23.8 + 12.9 + 10.6 + 13.8 = 61.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Advance Agrolife LtdADVANCE | 56.3/100Thin evidence · provisional56% evidence | TURNING | 21.4/35 Revenue 27% · PAT 37.6% · OPM change 4.3 pp 83% evidence | 14.8/25 ROCE 19.3% · OPM 10.8% 95% evidence | 10.1/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 21.4 + 14.8 + 10.1 + 10 = 56.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7UPL LtdUPL | 54.2/100Mixed-positive evidence90% evidence | ASLEEP | 20.6/35 Revenue 11.2% · PAT 100% · OPM change -1 pp 88% evidence | 9.3/25 ROCE 10.1% · OPM 19% 100% evidence | 12.5/20 P/E 28.3× · PEG 0.5 100% evidence | 11.8/20 RS sector 4.9% · RS bench -12.2% · 1Y -16.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 9.3 + 12.5 + 11.8 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8India Pesticides LtdIPL | 54.0/100Mixed-positive evidence81% evidence | TURNING | 20.0/35 Revenue 17% · PAT 10.1% · OPM change -2 pp 95% evidence | 13.6/25 ROCE 16.7% · OPM 14% 95% evidence | 14.1/20 P/E 16.5× · PEG — 50% evidence | 6.3/20 RS sector -11.9% · RS bench -12.1% · 1Y -27.3%4 of 11 weeks ahead 70% evidence |
| Exact sum: 20 + 13.6 + 14.1 + 6.3 = 54 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Jubilant Ingrevia LtdJUBLINGREA | 52.7/100Mixed-positive evidence93% evidence | FADING | 18.2/35 Revenue 11% · PAT 11.2% · OPM change 1 pp 100% evidence | 10.2/25 ROCE 11.4% · OPM 15% 100% evidence | 6.4/20 P/E 36.8× · PEG 2.37 65% evidence | 17.9/20 RS sector 11.8% · RS bench 7.8% · 1Y -5.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 10.2 + 6.4 + 17.9 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Bharat Rasayan LtdBHARATRAS | 51.6/100Mixed-positive evidence77% evidence | ASLEEP | 17.1/35 Revenue 5.8% · PAT 3.5% · OPM change 4 pp 83% evidence | 16.5/25 ROCE 17.4% · OPM 16% 95% evidence | 14.7/20 P/E 13.3× · PEG — 50% evidence | 3.3/20 RS sector -33.2% · RS bench -34.6% · 1Y -51.5%0 of 11 weeks ahead 70% evidence |
| Exact sum: 17.1 + 16.5 + 14.7 + 3.3 = 51.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Bhagiradha Chemicals & Industries LtdBHAGCHEM | 51.0/100Mixed-positive evidence88% evidence | TURNING | 23.6/35 Revenue 21.7% · PAT 31.1% · OPM change 7.3 pp 65% evidence | 5.8/25 ROCE 4.5% · OPM 12.3% 100% evidence | 2.0/20 P/E 207× · PEG 3.04 100% evidence | 19.6/20 RS sector 22.5% · RS bench 17.9% · 1Y -0.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 5.8 + 2 + 19.6 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12GSP Crop Science LtdGSPCROP | 50.4/100Thin evidence · provisional59% evidence | TURNING | 16.5/35 Revenue 21.2% · PAT 37.8% · OPM change -4 pp 88% evidence | 14.3/25 ROCE 19% · OPM 9% 100% evidence | 9.6/20 P/E 26.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 16.5 + 14.3 + 9.6 + 10 = 50.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Dhanuka Agritech LtdDHANUKA | 46.6/100Mixed-negative evidence96% evidence | ASLEEP | 8.3/35 Revenue 0.9% · PAT -5.3% · OPM change -2.5 pp 88% evidence | 19.1/25 ROCE 28.3% · OPM 22.5% 100% evidence | 13.0/20 P/E 15.6× · PEG 1.72 100% evidence | 6.2/20 RS sector -12.4% · RS bench -16.2% · 1Y -40.9%4 of 12 weeks ahead 100% evidence |
| Exact sum: 8.3 + 19.1 + 13 + 6.2 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Sumitomo Chemical India LtdSUMICHEM | 45.4/100Mixed-negative evidence94% evidence | TURNING | 12.1/35 Revenue -3.6% · PAT 3.9% · OPM change 1 pp 100% evidence | 19.0/25 ROCE 22.1% · OPM 22% 100% evidence | 4.0/20 P/E 44.6× · PEG 4 100% evidence | 10.3/20 RS sector -8.2% · RS bench 6% · 1Y -12.8%9 of 10 weeks ahead 70% evidence |
| Exact sum: 12.1 + 19 + 4 + 10.3 = 45.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 15Rallis India LtdRALLIS | 45.3/100Mixed-negative evidence91% evidence | ASLEEP | 16.1/35 Revenue 7.3% · PAT -28.4% · OPM change 2.6 pp 95% evidence | 9.3/25 ROCE 12.8% · OPM 15.2% 95% evidence | 11.4/20 P/E 26.7× · PEG 0.89 100% evidence | 8.5/20 RS sector -1.8% · RS bench -20.7% · 1Y -39.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.1 + 9.3 + 11.4 + 8.5 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16NACL Industries LtdNACLIND | 44.9/100Mixed-negative evidence94% evidence | TURNING | 28.1/35 Revenue 11.9% · PAT 100% · OPM change 3 pp 100% evidence | 4.4/25 ROCE 8.1% · OPM 11% 100% evidence | 3.8/20 P/E 171× · PEG 2.02 100% evidence | 8.6/20 RS sector -12.5% · RS bench 3.8% · 1Y -26.9%10 of 10 weeks ahead 70% evidence |
| Exact sum: 28.1 + 4.4 + 3.8 + 8.6 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Astec Lifesciences LtdASTEC | 44.9/100Mixed-negative evidence63% evidence | ASLEEP | 23.3/35 Revenue 9.4% · PAT 47.7% · OPM change 11.2 pp 71% evidence | 2.6/25 ROCE -5.4% · OPM -0.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.0/20 RS sector -3.5% · RS bench -9.3% · 1Y -27.2%7 of 10 weeks ahead 70% evidence |
| Exact sum: 23.3 + 2.6 + 10 + 9 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Meghmani Organics LtdMOL | 44.3/100Mixed-negative evidence74% evidence | TURNING | 20.6/35 Revenue -7.8% · PAT 100% · OPM change 7 pp 95% evidence | 9.4/25 ROCE 6.7% · OPM 18% 95% evidence | 10.2/20 P/E 21.3× · PEG — 15% evidence | 4.1/20 RS sector -33.7% · RS bench -13.6% · 1Y -42.8%3 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 9.4 + 10.2 + 4.1 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Insecticides India LtdINSECTICID | 43.8/100Mixed-negative evidence77% evidence | ASLEEP | 11.9/35 Revenue 7% · PAT -1.4% · OPM change -2 pp 83% evidence | 13.0/25 ROCE 15.8% · OPM 6% 95% evidence | 11.7/20 P/E 13.5× · PEG — 50% evidence | 7.2/20 RS sector -8.5% · RS bench -9.5% · 1Y -38.7%7 of 10 weeks ahead 70% evidence |
| Exact sum: 11.9 + 13 + 11.7 + 7.2 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Excel Industries LtdEXCELINDUS | 43.1/100Mixed-negative evidence70% evidence | TURNING | 14.4/35 Revenue 12% · PAT -11.8% · OPM change 0 pp 83% evidence | 8.6/25 ROCE 6.1% · OPM 8% 95% evidence | 10.9/20 P/E 16.4× · PEG — 15% evidence | 9.2/20 RS sector -4.6% · RS bench -2.6% · 1Y -27.3%2 of 10 weeks ahead 70% evidence |
| Exact sum: 14.4 + 8.6 + 10.9 + 9.2 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Epigral LtdEPIGRAL | 41.3/100Mixed-negative evidence94% evidence | ASLEEP | 6.5/35 Revenue 4.8% · PAT -37.4% · OPM change -2 pp 100% evidence | 14.3/25 ROCE 15.5% · OPM 25% 100% evidence | 16.5/20 P/E 17.3× · PEG 0.43 100% evidence | 4.0/20 RS sector -32.9% · RS bench -17.5% · 1Y -40.9%7 of 10 weeks ahead 70% evidence |
| Exact sum: 6.5 + 14.3 + 16.5 + 4 = 41.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22P I Industries LtdPIIND | 40.9/100Mixed-negative evidence90% evidence | ASLEEP | 6.6/35 Revenue -15.9% · PAT -20.5% · OPM change -3 pp 88% evidence | 15.5/25 ROCE 15% · OPM 22% 100% evidence | 10.6/20 P/E 34.7× · PEG 1.71 100% evidence | 8.2/20 RS sector -3.4% · RS bench -15.3% · 1Y -32.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 6.6 + 15.5 + 10.6 + 8.2 = 40.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Best Agrolife LtdBESTAGRO | 29.7/100Adverse evidence81% evidence | TURNING | 7.9/35 Revenue -24.1% · PAT -56.5% · OPM change 8 pp 95% evidence | 9.0/25 ROCE 5.2% · OPM 20% 95% evidence | 7.0/20 P/E 22.9× · PEG — 50% evidence | 5.8/20 RS sector -30.7% · RS bench -8.5% · 1Y -36.9%1 of 11 weeks ahead 70% evidence |
| Exact sum: 7.9 + 9 + 7 + 5.8 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Heranba Industries LtdHERANBA | 25.7/100Adverse evidence65% evidence | ASLEEP | 11.7/35 Revenue 13.1% · PAT -80% · OPM change -2.7 pp 62% evidence | 1.2/25 ROCE -1.6% · OPM -7% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.8/20 RS sector -22% · RS bench -25.7% · 1Y -51.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 1.2 + 10 + 2.8 = 25.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Dharmaj Crop Guard Ltd's share price today?
Dharmaj Crop Guard Ltd trades at ₹268, −18.2% over the past year. The company is valued at ₹905 Cr. The stock sits at 28% of its 52-week range of ₹228–₹372, +1.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 9 weeks in. — as of 31 July 2026.
What were Dharmaj Crop Guard Ltd's latest quarterly results?
Dharmaj Crop Guard Ltd reported revenue of ₹234 Cr and net profit of ₹4.0 Cr for the Mar 26 quarter. Earnings per share were ₹1.17. The operating margin was 4.5%, 2.7 pp higher than a year earlier. — as of 31 July 2026.
What is Dharmaj Crop Guard Ltd's revenue?
Dharmaj Crop Guard Ltd reported revenue of ₹234 Cr in the Mar 26 quarter, +11.4% year on year. For the full FY26 fiscal year, revenue was ₹1,138 Cr (+19.7%). Over the last 2 years revenue compounded at 31.9% a year. — as of 31 July 2026.
What is Dharmaj Crop Guard Ltd's profit?
Dharmaj Crop Guard Ltd earned ₹4.0 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹55.0 Cr. The operating margin ran 4.5% in the latest quarter. — as of 31 July 2026.
What is Dharmaj Crop Guard Ltd's market cap?
Dharmaj Crop Guard Ltd's market capitalisation is ₹905 Cr at a share price of ₹268. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Dharmaj Crop Guard Ltd's P/E ratio?
Dharmaj Crop Guard Ltd trades at a P/E of 16.6×, at the 30th percentile of its own 1-year range, against a long-run median of 17.2×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Dharmaj Crop Guard Ltd pay a dividend?
No — Dharmaj Crop Guard Ltd has recorded a dividend payout of 0% of profit in each of its last 3 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is Dharmaj Crop Guard Ltd overvalued?
On its own history, Dharmaj Crop Guard Ltd looks cheap against its own history: its P/E of 16.6× has been cheaper only 30% of the time in 1 years (long-run median 17.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
How is Dharmaj Crop Guard Ltd performing?
Dharmaj Crop Guard Ltd is in a confirmed uptrend, 9 weeks in. Against the NIFTY 500 it has been behind on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is Dharmaj Crop Guard Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 9 of stage 2), trading +1.8% versus its 200-day average and at 28% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Dharmaj Crop Guard Ltd beating the market?
Not lately — on a trailing-13-week view Dharmaj Crop Guard Ltd is currently behind the NIFTY 500 (5 weeks and counting; last ahead the week of 2026-07-01), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 3.6 years the stock moved +7% against the NIFTY 500's +47% — behind the index over the full window. — as of 31 July 2026.
Will Dharmaj Crop Guard Ltd's share price go up?
This page publishes no price forecast for Dharmaj Crop Guard Ltd. What it measures instead: the share price is ₹268, the price is in a confirmed uptrend 9 weeks in. Its P/E of 16.6× sits at the 30th percentile of its own 1-year range. — as of 31 July 2026.
Who owns Dharmaj Crop Guard Ltd?
Promoters hold 70.4% of Dharmaj Crop Guard Ltd, foreign institutions 3.1%, domestic institutions 0.5% and the public 26.0% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 3.8 points over 8 quarters. — as of 31 July 2026.
Does Dharmaj Crop Guard Ltd have too much debt?
No — Dharmaj Crop Guard Ltd's debt-to-equity is 0.29, and operating profit covers the interest bill 6×. FY26 borrowings were ₹132 Cr against equity of ₹449 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Dharmaj Crop Guard Ltd's capex?
Dharmaj Crop Guard Ltd spent ₹49.0 Cr on capital expenditure over the last 2 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹27.0 Cr, with ₹6.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Dharmaj Crop Guard Ltd's cash flow?
Dharmaj Crop Guard Ltd generated ₹28.0 Cr of operating cash flow in FY26 and ₹1.0 Cr of free cash flow after ₹27.0 Cr of capital spending. Reported profit that year was ₹55.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Dharmaj Crop Guard Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 55% of Dharmaj Crop Guard Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹28.0 Cr against reported profit of ₹55.0 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Dharmaj Crop Guard Ltd in its business cycle?
Dharmaj Crop Guard Ltd's FY26 operating margin was 9.0%, against a 3-year band of 8.0%–10.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 4.5%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Dharmaj Crop Guard Ltd story?
The sharpest disagreement: profits are rising, but only 55% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Dharmaj Crop Guard Ltd a stock worth studying right now?
This is not investment advice. The machine read: Dharmaj Crop Guard Ltd is coiled. The quarters are improving, yet the P/E sits at the 30th percentile of its own 1-year range — the business is moving before the market. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.